Margriet Vervoordeldonk

Margriet Vervoordeldonk, PhD, is a seasoned professional in clinical development and immunoinflammation with extensive experience in the biotechnology field. Currently serving as Senior Director Clinical Development & Clinical Science Lead at Galvani Bioelectronics since November 2016, Margriet has played a pivotal role in advancing neuromodulation therapies for chronic diseases. Prior experience at GSK involved directing neuromodulation strategies for chronic inflammatory diseases. Margriet's academic contributions include a lecturer position at AMC - Academisch Medisch Centrum and a history as a team leader and senior scientist there. Margriet also held leadership roles at Arthrogen (now MeiraGTx Netherlands B.V.), including Chief Operating Officer, and has a foundational background as a PhD student at the University of Utrecht. Margriet earned a PhD in Biochemistry from Utrecht University in 1991.